Amino Acid Substitutions in a Variant of IMP-1 Metallo-β-Lactamase

SHIZUKO IYOBE,¹* HARUKO KUSADOKORO,² JUNKO OZAKI,² NAOKI MATSUMURA,³ SHINZABURO MINAMI,³ SHIN HARUTA,² TETSUO SAWAI,² and KOJI O'HARA²

Laboratory of Drug Resistance in Bacteria, Gunma University School of Medicine, Maebashi,¹ Division of Microbial Chemistry, Faculty of Pharmaceutical Sciences, Chiba University, Chiba,² and Research Laboratory, Toyama Chemical Co., Ltd., Toyama,³ Japan

Received 8 October 1999/Returned for modification 31 January 2000/Accepted 5 May 2000

In the course of surveying for the carbapenem-hydrolyzing metallo- β -lactamase gene bla_{IMP} in pathogenic bacteria by the PCR method, we detected a gene encoding a variant metallo- β -lactamase, designated IMP-3, which differed from IMP-1 by having low hydrolyzing activity for penicillins and carbapenems. PCR product direct sequencing of a 2.2-kb segment revealed that the gene bla_{IMP-3} was located on a cassette inserted within a class I integron in the pMS390 plasmid. The 741-bp nucleotide sequence of bla_{IMP-3} was identical to that of bla_{IMP-1} , except for seven base substitutions. Among these were two, at nucleotide positions 314 and 640, which caused amino acid alterations. Hybrid *bla* genes were constructed from *bla_{IMP-3*} and *bla_{IMP-1*} by recombinant DNA techniques, and β -lactamases encoded by these genes were compared with those of the parents IMP-3 and IMP-1 under the same experimental conditions. The kinetic parameters indicated that the inefficient hydrolysis of benzylpenicillin, ampicillin, imipenem, and ceftazidime by IMP-3 was due to the substitution of glycine for serine at amino acid residue 196 in the mature enzyme. This alteration corresponded to the presence of guanine instead of an adenine at nucleotide position 640 of the *bla_{IMP-3*} gene. This indicated that extension of the substrate profile in the metallo- β -lactamase IMP-1 compared to IMP-3 is the result of a one-step single-base mutation, suggesting that the gene *bla_{IMP-3*} is an ancestor of *bla_{IMP-1*}.

 β -Lactamases are enzymes that hydrolyze β -lactam antibiotics, conferring resistance to a variety of these antibiotics for most pathogenic bacteria. These enzymes have been classified phylogenetically based on their functional and molecular characteristics (5).

Molecular class B metallo- β -lactamases belonging to functional group 3a subclass B1 are characteristic in their broad substrate spectrum, which extends to most β -lactam antibiotics, except for monobactams, and have activities as penicillinases, cephalosporinases, and carbapenemases (5, 15, 23). They have been reported in *Bacillus cereus*, alkalophilic *Bacillus* sp., *Bacteroides fragilis, Pseudomonas aeruginosa, Serratia marcescens*, and *Klebsiella pneumoniae* (23). Among this group of metallo- β -lactamases, ESP from *P. aeruginosa* GN17203, IMP-1 from *S. marcescens* TN9106, and DK4 from *K. pneumoniae* are all plasmid mediated and were found to be the same enzyme because the nucleotide sequences of their genes are identical (14, 22; GenBank accession number D29636).

Genes $bla_{\rm ESP}$ and $bla_{\rm IMP}$, respectively encoding ESP and IMP-1 β -lactamase, were identified in the cassettes inserted in the integrons on plasmids (24). Both cassettes had the same nucleotide sequence, but they were found to be inserted into different integrons, class 1 integron 0 (In0) for the $bla_{\rm ESP}$ cassette (2, 14) and the class 3 integron for the $bla_{\rm IMP}$ cassette (1). This fact suggested that the $bla_{\rm IMP}$ ($bla_{\rm ESP}$) cassette has been disseminated among different integrons. Since In0 is reported to be widespread among clinical isolates of gram-negative bacilli and has insertions of single or multiple drug resistance genes (17), we surveyed clinical isolates for In0 bearing $bla_{\rm IMP}$ ($bla_{\rm ESP}$) by the PCR method, followed by an assay of

β-lactamase activity. In the process of these assays, we demonstrated the presence of a novel metallo-β-lactamase which was mediated by *Shigella flexneri* plasmid pMS390 (21). The β-lactamase, originally named MET-1 is a cephalosporinase, showing preferential hydrolysis of cephalosporins rather than penicillins or carbapenems. We examined the nucleotide sequence of the gene *bla*_{MET} to identify the amino acid substitutions affecting the substrate specificity in the MET-1 β-lactamase. On the basis of our findings, the gene and the enzyme were renamed *bla*_{IMP-3} and IMP-3 β-lactamase, respectively, to mesh with prior discoveries and nomenclature.

MATERIALS AND METHODS

Bacterial strains and plasmids. Plasmids pMS390 from *S. flexneri* JS19622 and pMS350 from *P. aeruginosa* GN17203 are the starting plasmids used for this study. Plasmid pMS390 was transferred by conjugation to an *Escherichia coli* K-12 ML4905 strain for enzyme analysis (21), and the gene was cloned in *E. coli* K-12 JM83 for sequencing (this work). The metallo- β -lactamase gene *bla*_{ESP} of pMS350 (29) had been earlier cloned and sequenced (13, 14). Since the nucleotide sequence of *bla*_{ESP} was identical to that of *bla*_{IMP} from *S. marsescens* strain TN9106 (22), hereafter in this work the abbreviation *bla*_{IMP} is used for *bla*_{ESP} from pMS350.

The plasmid and host strain used for direct cloning of the PCR product were pT7Blue T-Vector with an ampicillin resistance marker and *E. coli* NovaBlue with a tetracycline resistance marker (Novagen), respectively. Cloning vectors used throughout were pHSG397 and pHSG398, which were

Cloning vectors used throughout were pHSG397 and pHSG398, which were multicopy vectors with a chloramphenicol resistance marker (27). *E. coli* K-12 JM83 was used as the host strain (28). The *Hin*dIII site on the multicloning region of pHSG398 was deleted for this experiment using the deletion kit (Takara Shuzo Co., Ltd.), forming the vector pHSG398 Δ Hd.

Recombinant plasmids pMS400, pMS500, pMS401, pMS501, pMS402, and pMS502 were constructed for these experiments.

Antibacterial agents. The β -lactam antibiotics used and their sources were as follows: cephaloridine and cephalothin, Shionogi & Co., Ltd.; cefotaxime, Hoechst Marion Roussel Ltd.; ceftazidime, Nippon Glaxo Ltd.; benzylpenicillin, Meiji Seika Kaisha, Ltd.; ampicillin, Toyama Chemical Co., Ltd.; imipenem, Banyu Pharmaceutical Co., Ltd.; and aztreonam, Bristol-Myers Squibb K. K.

Susceptibility tests. MICs were determined by an agar dilution method with sensitivity disk agar (Nissui Pharmaceutical Co.) (29).

^{*} Corresponding author. Mailing address: Laboratory of Drug Resistance in Bacteria, Gunma University School of Medicine, 3-39-22, Showa-Machi, Maebashi, 371-8511, Japan. Phone: 81-27-220-8087. Fax: 81-27-220-8088. E-mail: siyobe@akagi.sb.gunma-u.ac.jp.

Purification of β **-lactamase and assay of activity.** Preparation and purification of β -lactamases using *E. coli* JM83 strains harboring recombinant plasmids were performed according to a previously reported method (21).

β-Lactamase activity was determined spectrophotometrically at 30°C in 50 mM morpholinepropanesulfonic acid (MOPS) buffer (pH 7.0). The kinetic parameters were determined according to a procedure reported previously (21). Statistical data were obtained by the online analysis (UV absorption method and Lineweaver-Burk plot analysis on the computer) system by measuring the rate of hydrolysis (k_{cat}) and K_m values more than three times. When K_m values were too large for this system, they were obtained from Michaelis-Menten graphs by measuring the initial hydrolysis rates.

PCR amplification of the DNA segment. Primer sequences for PCR amplification were CGGATGAAGGCACGAAC (forward) and AAGCAGACTTGA CCTGA (reverse), constructed for detection of the $bla_{\rm IMP}$ cassette inserted in the integron In0 (14). The forward primer was part of the 5' conserved sequence of the In0 located 5 nucleotides upstream from the promoter region for $bla_{\rm IMP}$ (18), and the reverse primer was part of the 3' conserved sequence of the integron downstream from the $bla_{\rm IMP}$ gene cassettes (2, 17).

The PCR procedure consisted of 25 cycles of denaturation at 94°C for 1.5 min, annealing at 55°C for 1.5 min, and amplification at 72°C for 1.5 min, followed by an additional 7 min at 72°C using Premix *Taq* reagent (Takara Shuzo Co., Ltd.) with the Program Template Control System PC-700 (ASTEC Co., Ltd.).

Nucleotide sequencing. The PCR-amplified DNA segment was sequenced by a direct sequencing method using the Autosequencer ABI377 in the Gene Analysis Center of Takara Shuzou Co., Ltd.

Cloning of the PCR-amplified segment. The PCR product obtained by agarose gel electrophoresis was purified by adsorbing the DNA to a silica matrix using a DNA purification kit (Gene Mate; ISC BioExpress) and was ligated with pT7Blue T-Vector (Novagen) according to the manufacturer's protocol. Recombinant plasmids were introduced into the host strain *E. coli* NovaBlue, and the transformants were obtained as white colonies on a Luria agar plate containing X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (50 μ g/ml), IPTG (isopropyl-β-D-thiogalactopyranoside) (50 μ g/ml), tetracycline (15 μ g/ml), and ampicillin (50 μ g/ml).

RESULTS

Identification and nucleotide sequencing of the β-lactamase gene of pMS390. A DNA segment, approximately 2.2 kb in size, was obtained from the pMS390-containing *E. coli* ML4905 cells after PCR amplification, using primers for detection of the In0 sequence including the gene cassettes. The nucleotide sequence was determined by the PCR product direct-sequencing method. Within this segment, the gene composed of 741 bp was detected. The sequence of the gene (DDBJ accession number AB010417) was identical to that of *bla*_{IMP} (1, 14) (DDBJ accession number D78375) except for seven nucleotide substitutions. The gene was designated *bla*_{IMP-3} to correspond with the renaming of the metallo-β-lactamase mediated by pMS390 (21), which was originally named MET-1 and is now known as IMP-3 β-lactamase.

Two of the seven substitutions caused changes in amino acids between IMP-3 and IMP-1 β -lactamases. Substitution of an A with a G at both nucleotide positions 314 and 640 resulted in the replacement of the amino acid: Glu with Gly and Ser with Gly at amino acid positions 87 and 196, respectively, in the mature metallo- β -lactamase (23).

Cloning of the PCR-amplified segment. Three preparations of 2.2-kb segments, each obtained by independent PCR amplification, were ligated with the pT7Blue vector, and the recombinant plasmids were introduced by transformation into the host strain *E. coli* NovaBlue. The transformants were examined for cefotaxime resistance, which is conferred by the IMP-3 β -lactamase. The MIC of cefotaxime was raised from less than 0.5 µg/ml for the host strain to 64 µg/ml for transformants.

The nucleotide sequences of the recombinant plasmids obtained from the three independent experiments were examined by the PCR direct-sequencing method. Two of the plasmids had no misincorporation of nucleotides in the bla_{IMP-3} genes, and one of the two was selected for this experiment. The 2.2-kb segment was cleaved out at the *Bam*HI and *XbaI* sites flanking the insert in the multicloning region of the vector plasmid, subcloned into another vector (pHSG397), and introduced into *E. coli* JM83 cells by transformation. The transformants were selected for chloramphenicol resistance (marker of the vector). The recombinant plasmid thus obtained was named pMS400.

Preparation of hybrid metallo-β-lactamase genes from *bla*_{IMP-3} and *bla*_{IMP-1}. The k_{cat} (per second) of penicillin relative to that of cephaloridine by highly purified β-lactamases was reported to be rather low for IMP-3 (21) but high for IMP-1 (16, 23). As this difference is expected to be due to either or both of the two amino acid alterations between the two enzymes, we prepared hybrid genes from *bla*_{IMP-3} and *bla*_{IMP-1} and compared them with those of the parents IMP-3 and IMP-1 under the same experimental conditions.

The hybrid and parent genes were constructed from pMS400 and pMS500, the recombinant plasmids of pHSG397, with segments containing bla_{IMP-3} and bla_{IMP-1} , respectively (Fig. 1). The *SphI* segment of pMS500 was obtained from *P. aeruginosa* plasmid pMS350 (14).

First, the left (*Hin*dIII-*Sma*I [H-S]) and the right (*Sma*I-*Eco*RI [S-E]) segments of pMS400, respectively, including the nucleotide at position 314 or 640, were subcloned into pHSG398 (step 1). Second, the left (*Sph*I-*Sma*I [Sp-S]) segment of pMS500 was subcloned into pHSG398 Δ Hd (step 2). Third, the H-S segment of the recombinant plasmid obtained in step 2 was cut out and replaced with the H-S segment of *bla*_{IMP-3} obtained in step 1 (step 3). Fourth, the S-E segment of pMS400 carrying the right part of *bla*_{IMP-3} (from step 1) was inserted into the step-3 plasmid, forming pMS401 which contained the whole *bla*_{IMP-3} gene. The same S-E segment was inserted into the plasmid obtained at step 2, forming a hybrid plasmid pMS402 consisting of the left part of *bla*_{IMP-1} and the right part of *bla*_{IMP-3}.

The right S-E segment of pMS500 was obtained using the EcoRI site in the multicloning region of the vector and inserted into the step-3 plasmid. A hybrid plasmid pMS502 was thus obtained, and consisted of the left part of bla_{IMP-3} and the right part of bla_{IMP-1} . The same S-E segment was inserted into the step-2 plasmid, thereby forming plasmid pMS501 which contained the whole bla_{IMP-1} gene.

The resulting four *bla* genes, from the two hybrids and their parents, were capable of expression under the common promoter derived from pMS500 provided by the integron portion (18).

Susceptibility to β -lactam antibiotics conferred by β -lactamases with amino acid substitutions. With the common background of the vector pHSG398ΔHd and the host strain E. coli K-12 JM83, MICs of various β-lactam antibiotics were examined and compared among the four strains producing different β -lactamases encoded by hybrid or parent *bla* genes (Table 1). The MIC of imipenem was rather low in the E. coli host carrying pMS500, as was expected from previous findings using E. coli clones carrying the bla_{IMP-1} gene of P. aeruginosa plasmid pMS350 (13). A distinct rise in the MIC of ampicillin was observed for strains carrying pMS501 and pMS502, in which the β -lactamases had the amino acid Ser at position 196, in comparison to MICs observed for strains carrying pMS401 and pMS402, in which the β -lactamases had the amino acid Gly instead of Ser at that position. The MICs of cephalothin for strains carrying pMS401 or pMS402 were fourfold higher than those for strains carrying pMS501 or pMS502. Neither amino acid substitution caused distinct changes in the MICs of other β -lactams. Amino acid replacement at position 87 of the β -lactamases did not affect the MIC levels, as seen in the two strains bearing pMS401 or pMS402 and in those bearing pMS501 or pMS502. The results suggested that the low MIC of ampicillin



FIG. 1. Construction of the hybrid and parent metallo- β -lactamase genes. The procedure is explained in Materials and Methods. The horizontal single lines represent multicloning regions of the vector plasmids flanking the inserts. The *Eco*RI (E) and *Hin*dIII (H) sites located in the multicloning regions are indicated above the lines. Inserts are shown by boxes, in which the regions of metallo- β -lactamase genes are shaded in black. The sites of the restriction enzymes are indicated above the boxes. Abbreviations not used in the text are B (*Bam*HI) and X (*Xba*I). The sites indicated under the boxes are P (for promoter) (14), G (for guanine), and A (for adenine).

and high MIC of cephalothin for strains carrying pMS401 and pMS402 resulted from a single amino acid alteration from Ser to Gly at position 196.

Kinetic parameters of β-lactamases with amino acid substitutions. β-Lactamase activities by enzymes encoded by the four kinds of *bla* genes were assayed spectrophotometrically using highly purified enzymes. Kinetic parameters for the hydrolysis of various β-lactam antibiotics were determined under the same assay conditions (Table 2). It was confirmed that the kinetic parameters of IMP-3 and IMP-1 were in good agreement with those previously estimated in an *E. coli* strain carrying pMS390 (for both k_{cat} and K_m) and in a *P. aeruginosa* strain carrying pMS350 (for K_m), respectively (21, 29). Aztreonam-hydrolyzing activities were undetectable in all four enzymes ($k_{\rm cat} < 0.06 \ {\rm s}^{-1}$).

No significant difference in kinetic parameters was observed between the enzyme pairs of pMS401 and pMS402 or between those of pMS501 and pMS502, though the enzymes of the former pair were clearly distinguishable from those of the latter. This indicated that the differences in kinetic parameters were caused by the substitution of Gly for Ser at position 196 but not of Gly for Glu at position 87.

As indicated in Table 2, the single amino acid alteration from Ser to Gly at position 196 affected enzyme activities as reflected in the values of either k_{cat} or K_m , or both, and lowered hydrolysis efficiencies (k_{cat}/K_m) more than 1 order of mag-

TABLE 1. Resistance levels conferred by the parent and hybrid metallo-β-lactamases^a

Plasmid	β-Lactamase	Amino acid residue at position:		MIC (μ g/ml) of ^b :							
		87	196	LOR	CEF	CTX	CAZ	AMP	IMP	ATM	
pMS401	IMP-3	Gly	Gly	64	512	64	64	8	1	< 0.5	
pMS402	Hybrid	Glu	Gly	64	512	64	64	8	1	< 0.5	
pMS502	Hybrid	Gly	Ser	32	128	32	64	64	2	< 0.5	
pMS501	IMP-1	Glu	Ser	32	128	32	64	64	2	< 0.5	
pHSG398 ∆ Hd				2	8	< 0.5	< 0.5	4	< 0.5	< 0.5	
None				2	8	< 0.5	< 0.5	4	< 0.5	< 0.5	

^a Host strain: E. coli K-12 JM83.

^b LOR, cephaloridine; CEF, cephalothin; CTX, cefotaxime; CAZ, ceftazidime; AMP, ampicillin; IMP, imipenem; ATM, aztreonam.

TABLE 2. Kinetic parameters for hydrolysis of various β -lactam antibiotics by the hybrid and parent metallo- β -lactamases

Plasmid	Enzyme	Amino acid at position:		Kinetic parameter	Antibiotic ^a							
		87	196	x	LOR	CEF	CTX	CAZ	PEN	AMP	IMP	
pMS401	IMP-3	Gly	Gly	$k_{cat} (s^{-1}) \ K_m (\mu M) \ k_{cat}/K_m (\mu M^{-1} s^{-1})$	$\begin{array}{c} 221 \pm 15^{b} \\ 248 \pm 39^{b} \\ 0.89 \end{array}$	223 ± 22 9.9 ± 1.3 22.5	$\begin{array}{c} 40.1 \pm 2.6 \\ 3.1 \pm 0.3 \\ 12.9 \end{array}$	$\begin{array}{c} 4.5 \pm 0.4^{b} \\ 128 \pm 17^{b} \\ 0.035 \end{array}$	$\begin{array}{c} 14.3 \pm 0.8^{b} \\ 370 \pm 59^{b} \\ 0.039 \end{array}$	$\begin{array}{c} 7.4 \pm 1.2^{b} \\ 464 \pm 145^{b} \\ 0.016 \end{array}$	$\begin{array}{c} 92.3 \pm 2^{b} \\ 1140 \pm 40^{b} \\ 0.08 \end{array}$	
pMS402	Hybrid	Glu	Gly	$k_{cat} (s^{-1}) \ K_m (\mu M) \ k_{cat}/K_m (\mu M^{-1} s^{-1})$	$\begin{array}{c} 268 \pm 5^{b} \\ 215 \pm 17^{b} \\ 1.25 \end{array}$	384 ± 11 9.8 ± 0.3 39.2	$54.8 \pm 5.3 \\ 3.0 \pm 0.3 \\ 18.3$	$\begin{array}{c} 3.6 \pm 0.2^b \\ 118 \pm 19^b \\ 0.031 \end{array}$	$\begin{array}{c} 21.6 \pm 1.0^{b} \\ 464 \pm 60^{b} \\ 0.047 \end{array}$	$\begin{array}{c} 11.8 \pm 1.4^{b} \\ 437 \pm 105^{b} \\ 0.027 \end{array}$	$\begin{array}{c} 132 \pm 8^{b} \\ 1280 \pm 120^{b} \\ 0.10 \end{array}$	
pMS502	Hybrid	Gly	Ser	$ \begin{array}{l} k_{\rm cat}~({\rm s}^{-1})\\ K_m~(\mu{\rm M})\\ k_{\rm cat}/K_m~(\mu{\rm M}^{-1}~{\rm s}^{-1}) \end{array} $	$\begin{array}{c} 38.4 \pm 1.2 \\ 7.1 \pm 0.1 \\ 5.4 \end{array}$	$\begin{array}{c} 43.2 \pm 1.7 \\ 2.3 \pm 0.1 \\ 18.8 \end{array}$	16.5 ± 1.3 1.3 ± 0.2 12.7	$\begin{array}{c} 11.3 \pm 0.3 \\ 31.8 \pm 1.5 \\ 0.36 \end{array}$	282 ± 19 216 ± 13 1.3	87.0 ± 2.7 110 ± 4.9 0.8	90.8 ± 5.3 33.2 ± 1.9 2.7	
pMS501	IMP-1	Glu	Ser	$ \begin{array}{l} k_{\mathrm{cat}} \left(\mathrm{s}^{-1}\right) \\ K_m \left(\mathrm{\mu}\mathrm{M}\right) \\ k_{\mathrm{cat}}/K_m \left(\mathrm{\mu}\mathrm{M}^{-1} \; \mathrm{s}^{-1}\right) \end{array} $	$\begin{array}{c} 62.0 \pm 3.0 \\ 7.2 \pm 0.4 \\ 8.6 \end{array}$	$\begin{array}{c} 65.0 \pm 2.9 \\ 2.0 \pm 0.1 \\ 32.5 \end{array}$	$\begin{array}{c} 22.5 \pm 1.9 \\ 1.4 \pm 0.1 \\ 16.1 \end{array}$	$\begin{array}{c} 16.3 \pm 0.9 \\ 46.0 \pm 1.4 \\ 0.35 \end{array}$	$461 \pm 17 \\ 241 \pm 10 \\ 1.9$	$162 \pm 15 \\ 140 \pm 9 \\ 1.2$	$127 \pm 11 \\ 30.0 \pm 3.9 \\ 4.2$	

^a PEN, benzylpenicillin; see footnote b of Table 1 for other abbreviations.

^b Obtained from Michaelis-Menten graph; see Materials and Methods.

nitude for ceftazidime, benzylpenicillin, ampicillin, and imipenem.

DISCUSSION

The IMP-3 (renamed from MET-1) β -lactamase of plasmid pMS390 had been previously purified and revealed to be a cephalosporinase-type metallo- β -lactamase with low hydrolyzing activity for penicillins and carbapenems (21). In contrast, the IMP-1 β -lactamase, which is widespread among clinical strains, differed in its broad substrate spectrum of β -lactam antibiotics, including effective hydrolysis of penicillins and carbapenems (16, 22, 29). Sequence analysis of the gene *bla*_{IMP-3} revealed that the enzymes were identical except for two amino acid substitutions caused by two base replacements in the genes.

Hybrid *bla* genes obtained from bla_{IMP-1} and bla_{IMP-3} were constructed under a common promoter by recombination DNA techniques using a common vector and host strain of *E. coli*. Kinetic parameters for hydrolysis of various β -lactam antibiotics by the purified enzymes were estimated under the same assay conditions. The kinetic parameters of hybrid and parent β -lactamases indicated that the more potent hydrolysis of ceftazidime, benzylpenicillin, ampicillin, and imipenem could be acquired by a single amino acid substitution, i.e., Ser for Gly at position 196. The other substitution, Glu for Gly at position 87, had no effect on the substrate profiles examined so far, although further detailed analysis of enzyme kinetics, including affinity to metallo ions, remains to be carried out.

The amino acid sequences at the comparable regions of group 3a subclass B1 metallo- β -lactamases have been identified (23). The amino acid corresponding to that at position 196 in β -lactamases from *B. cereus, Bacillus* sp., and *B. fragilis* is reported to be Gly, the same amino acid found in the newly identified IMP-3 β -lactamase, which differs from IMP-1 β -lactamase. This amino acid lies just ahead of His, which has been identified as interacting with a Zn^{2+} cofactor (23). The association of the changed amino acid with the His amino acid remains unexplored, and the coincidence may be interesting to examine in terms of its affect on metallo ion interaction.

The results indicated that only a single-step mutation of the

base G to A at nucleotide position 640 of bla_{IMP-3} extended the substrate profile of the IMP-3 to that of the IMP-1-type β -lactamase and conferred resistance to ampicillin in E. coli. Evolution of β -lactamases from a narrow to an extended spectrum of substrates was well analyzed in TEM- and SHV-type enzymes belonging to the class A β -lactamases (3, 4, 8, 9, 15). These β-lactamases, called extended-spectrum β-lactamases (ESBLs), have been conferred with hydrolyzing activities against the extended-spectrum β -lactam antibiotics by point mutations. Extension of the substrate spectrum by amino acid substitutions also has been reported in an OXA-type β-lactamase belonging to the class D enzymes (6, 7, 10). In a class C β -lactamase of *Enterobacter cloacae*, the substrate spectrum expansion was caused by a duplication of three amino acids which was attributed to a tandem duplication of a 9-nucleotide sequence in the parent enzyme (20). None of the ESBLs derived from class A, C, and D enzymes have hydrolyzing activities for carbapenems (5).

The metallo- β -lactamase IMP-1, which belongs to the class B β -lactamases, was characteristic in its carbapenem-hydrolyzing activity and had already been noted as an ESBL when it was first identified in a *P. aeruginoisa* plasmid (29) and later in gram-negative rods (11, 12, 19, 25, 26). Therefore, IMP-3 (originally designated MET-1) β -lactamase mediated by plasmid pMS390 could be considered an ancestor of IMP-1 β -lactamase. The gene could be mobilized as part of a cassette among integrons located on various plasmids, becoming widely disseminated among gram-negative bacteria, and conferring resistance to almost all β -lactam antibiotics.

ACKNOWLEDGMENTS

This work was supported by a grant-in-aid for Scientific Research (08670300) from the Ministry of Education, Science, Sports, and Culture, Japan, and by a grant for Molecular Characterization of Antibiotic Resistance from the Ministry of Health and Welfare, Japan.

REFERENCES

- Arakawa, Y., M. Murakami, K. Suzuki, R. Wacharotayankun, S. Ohsuka, H. Ito, N. Kato, and M. Ohta. 1995. A novel integron-like element carrying the metallo-β-lactamase gene bla_{IMP}. Antimicrob. Agents Chemother. 39:1612– 1615.
- Bissonnette, L., and P. H. Roy. 1992. Characterization of In0 of *Pseudomo-nas aeruginosa* plasmid pVS1, an ancestor of integrons of multiresistance

plasmids and transposons of gram-negative bacteria. J. Bacteriol. 174:1248–1257.

- Blanzquez, J., M. I. Morosini, M. C. Negri, M. Gonzalez-Leiza, and F. Baquero. 1995. Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM β-lactamases. Antimicrob. Agents Chemother. 39:145–149.
- 4. Bush, K., and G. A. Jacoby. 1977. Nomenclature of TEM β -lactamases. J. Antimicrob. Chemother. **39**:1–3.
- Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211–1233.
- Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1996. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 39:1881–1884.
- Danel, F., L. M. C. Hall, D. Gur, and D. M. Livermore. 1997. OXA-15, an extended-spectrum variant of OXA-2 β-lactamase, isolated from a *Pseudo-monas aeruginosa* strain. Antimicrob. Agents Chemother. 41:785–790.
- Davies, J. 1995. Inactivation of antibiotics and the dissemination of resistance genes. Science 246:375–382.
- Du Bois, S. K., M. S. Marriott, and S. B. Amyes. 1995. TEM- and SHVderived extended-spectrum β-lactamases: relationship between selection, structure and function. J. Antimicrob. Chemother. 35:7–22.
- Hall, L. M. C., D. M. Livermore, D. Gur, M. Akova, and H. E. Akalin. 1993. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 37:1637– 1644.
- Hirakawa, Y., K. Izumikawa, T. Yamaguchi, H. Takemura, H. Tanaka, R. Yoshida, J. Matsuda, M. Nakano, K. Tomono, S. Maesaki, M. Kaku, Y. Yamada, S. Kamihira, and S. Kohno. 1998. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-β-lactamase gene *bla*_{IMP}. Antimicrob. Agents Chemother. 42:2006–2011.
- Ito, H., Y. Arakawa, S. Ohsuka, R. Wacharotayankun, N. Kato, and M. Ohta. 1995. Plasmid-mediated dissemination of the metallo-β-lactamase gene *bla*_{IMP} among clinically isolated strains of *Serratia marcescens*. Antimicrob. Agents Chemother. **39**:824–829.
- Iyobe, S., M. Tsunoda, and S. Mitsuhashi. 1994. Cloning and expression in Enterobacteriaceae of the extended-spectrum β-lactamase gene from a *Pseudomonas aeruginosa* plasmid. FEMS Microbiol. Lett. 121:175–180.
- Iyobe, S., S. Minami, and H. Yamada. 1996. Insertion of a carbapenemase gene cassette into an integron of a *Pseudomonas aeruginosa* plasmid. J. Antimicrob. Chemother. 38:1114–1115.
- Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35:1697–1704.
- Laraki, N., N. Franceschini, G. M. Rossolini, P. Santucci, C. Meunier, E. De Pauw, G. Amicosante, J. M. Frere, and M. Galleni. 1999. Biochemical char-

acterization of the *Pseudomonas aeruginosa* 101/1477 metallo-β-lactamase IMP-1 produced by *Escherichia coli*. Antimicrob. Agents Chemother. **43**: 902–906.

- Levesque, C., L. Piche, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185–191.
- Levesque, C., S. Brassard, J. Lapointe, and P. H. Roy. 1994. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene 142:49–54.
- Minami, S., M. Akama, H. Araki, Y. Watanabe, H. Narita, S. Iyobe, and S. Mitsuhashi. 1996. Imipenem and cephem resistant *Pseudomonas aeruginosa* carrying plasmids for class B β-lactamases. J. Antimicrob. Chemother. 37: 433–444.
- Nukaga, M., S. Haruta, K. Tanimoto, K. Kogure, K. Taniguchi, M. Tamaki, and T. Sawai. 1995. Molecular evolution of a class C β-lactamase extending its substrate specificity. J. Biol. Chem. 270:5729–5735.
- O'Hara, K., S. Haruta, T. Sawai, M. Tsunoda, and S. Iyobe. 1998. Novel metallo β-lactamase mediated by a *Shigella flexneri* plasmid. FEMS Microbiol. Lett. 162:201–206.
- 22. Osano, E., Y. Arakawa, R. Wacharotayankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura, and N. Kato. 1994. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of *Serratia marcescens* that shows imipenem resistance. Antimicrob. Agents Chemother. 38:71–78.
- Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 41:223–232.
- Recchia, G. D., and R. M. Hall. 1995. Gene casettes: a new class of mobile element. Microbiology 141:3015–3027.
- Senda, K., Y. Arakawa, K. Nakashima, H. Ito, S. Ichiyama, K. Shimokata, N. Kato, and M. Ohta. 1996. Multifocal outbreaks of metallo-β-lactamaseproducing *Pseudomonas aeruginosa* resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob. Agents Chemother. 40:349–353.
- Senda, K., Y. Arakawa, S. Ichiyama, K. Nakashima, H. Ito, S. Ohsuka, K. Shimokata, N. Kato, and M. Ohta. 1996. PCR detection of metallo-β-lactamase gene (*bla*_{IMP}) in gram-negative rods resistant to broad-spectrum β-lactams. J. Clin. Microbiol. 34:2909–2913.
- Takeshita, S., M. Sato, M. Oba, W. Masahashi, and T. Hashimoto-Gotoh. 1987. High-copy number and low-copy number plasmid vectors for *lacZα*complementation and chloramphenicol- or kanamycin-resistance selection. Gene 61:63–74.
- Vieira, J., and J. Messing. 1982. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis, and sequencing with synthetic universal primers. Gene 19:259–268.
- Watanabe, M., S. Iyobe, M. Inoue, and S. Mitsuhashi. 1991. Transferable imipenem resistance in *Pseudomonas aeruginosa*. Antimicrob. Agents Chemother. 35:147–151.